Please login to the form below

Not currently logged in
Email:
Password:

abemaciclib

This page shows the latest abemaciclib news and features for those working in and with pharma, biotech and healthcare.

Novartis claims a rare win at ESMO for PI3K inhibitor class

Novartis claims a rare win at ESMO for PI3K inhibitor class

6 inhibitor, a newer drug group which includes Novartis’own Kisqali (ribociclib), Pfizer’s Ibrance (palbociclib) and Eli Lilly’s Verzenio (abemaciclib).

Latest news

More from news
Approximately 7 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics